Poland· PL-100067320
Tracrium
A atracurium product containing atracurii besilas, registered in Poland by Aspen Pharma Trading Ltd.. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Atracurium is registered in 13 of 19 countries.
Countries holding a registration under ATC M03AC04 (atracurium), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Atracurium · ATC M03AC04
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Finlandprice
- Franceprice
- Germany
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Atracurii besilas
- Manufacturer
- Aspen Pharma Trading Ltd.
- Country
- Poland (PL)
- ATC code
- M03AC04
- ATC class
- Atracurium
- Defined daily dose
- 38.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 5
- gtin05909990277711
- gtin05060249174516
- gtin05909990277728
- gtin05060598251470
- gtin05909990277735
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
60 interactions on record for atracurium.
Graded by severity as the source publishes them — 12 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Atracurium · interactions on record
60 records
- 12 severe
- 44 moderate
- 4 minor
Most severe, free to view
- NeomycinA07AA01severe
- StreptomycinA07AA04severe
- Polymyxin BA07AA05severe
- ParomomycinA07AA06severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Atracurium in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandAtracurium Labatec 10 mg/ml, solution injectable / pour perfusionLabatec Pharma SA
- SpainBESILATO DE ATRACURIO KALCEKS 10 MG/ML SOLUCION INYECTABLE Y PARA PERFUSION EFGKalceks As
- NetherlandsTracrium 10 mg/ml oplossing voor injectie/infusieAspen Pharma Trading Limited
- United KingdomAtracurium besilate 10mg/5ml solution for injection vialsSpecial Order
- FranceATRACURIUM HIKMA 10 mg/mL, solution injectable/pour perfusionHIKMA FARMACEUTICA (PORTUGAL)
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6742ef8e-8f59-4285-8c9f-c4f4e71a695f GET /v1/drugs/6742ef8e-8f59-4285-8c9f-c4f4e71a695f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań lub infuzji",
"source": "urpl",
"strength": "10 mg/ml",
"packaging": "05909990277711 ¦ Lz ¦ 10113\n5 amp. 2,5 ml\n¦ UR/Z/4c/096/22 - 05060249174516\n05909990277728 ¦ Lz ¦ 14133\n5 amp. 5 ml\n¦ UR/Z/4c/063/22 - 05060598251470 ¦ UR/Z/4c/084/22 - 05060598251470\n05909990277735 ¦ Lz ¦ Skasowane ¦ 14134\n2 amp. 25 ml",
"substance": "Atracurii besilas 10 mg/ml",
"common_name": "Atracurii besilas",
"pl_product_id": "100067320",
"pozwolenie_nr": "02777",
"auth_procedure": "NAR",
"authorisation_validity": "Bezterminowe"
}See everything about atracurium.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.